Literature DB >> 10397706

Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins.

M Maurice1, S Mazur, F J Bullough, A Salvetti, M K Collins, S J Russell, F L Cosset.   

Abstract

Interleukin-2 (IL-2) is a cytokine that induces the proliferation of certain IL-2 receptor expressing quiescent cells. Human IL-2 was fused to the amino-terminus of amphotropic murine leukemia virus (MLV) envelope glycoproteins. Retroviral vectors were pseudotyped with both the IL-2 chimeric envelope and the wild-type amphotropic MLV envelope. The chimeric IL-2 glycoproteins were incorporated on retroviral vectors and the IL-2-displaying vector particles could bind specifically to cell surface IL-2 receptors. In addition, the IL-2-displaying vectors could infect proliferating cells through amphotropic receptors irrespective of whether the cells expressed the IL-2 receptor. IL-2-displaying vector particles could also transiently stimulate the cell cycle entry and proliferation of several IL-2-dependent cell lines. Finally, retroviral vectors displaying IL-2 could efficiently transduce G0/G1-arrested cells expressing the IL-2 receptor at a 34-fold higher efficiency compared with vectors with unmodified envelopes. This new strategy, whereby C-type retroviral vector particles display a ligand that activates the cell cycle of the target cells at the time of virus entry, may represent an alternative to lentivirus-derived retroviral vectors for the infection of quiescent cells. In addition, upon infection of an heterogeneous population of nonproliferating cells, MLV-retroviral vectors that display cytokines/growth factors will allow the transgene of interest to be integrated specifically in quiescent cells expressing the corresponding cytokine/growth factor receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397706

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.

Authors:  S Snitkovsky; T M Niederman; B S Carter; R C Mulligan; J A Young
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 2.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 3.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 4.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

5.  General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines.

Authors:  Hans J Kueng; Victoria M Leb; Daniela Haiderer; Graça Raposo; Clotilde Thery; Sophia V Derdak; Klaus G Schmetterer; Alina Neunkirchner; Christian Sillaber; Brian Seed; Winfried F Pickl
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

Review 6.  Current advances in retroviral gene therapy.

Authors:  Youngsuk Yi; Moon Jong Noh; Kwan Hee Lee
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 7.  Towards Physiologically and Tightly Regulated Vectored Antibody Therapies.

Authors:  Audrey Page; Floriane Fusil; François-Loïc Cosset
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.